TGen
Jumpcode Genomics, TGen Partner to Test Metagenomic Approaches for COVID Detection
The company and institute are collaborating on the development of a diagnostic assay that uses Jumpcode's CRISPR-based reagents and TGen's NGS technology.
As diagnostics firms develop a new wave of COVID-19 tests using next-gen sequencing, TGen researchers are also adding CRISPR-based sample prep to their kit.
The liquid biopsy method analyzes fragment ends within recurrently protected regions in cell-free DNA from a patient's urine sample.
Science Papers Examine Urine-Based Diagnostic Assays, Sleep Regulation
In Science this week: cell-free DNA from urine explored to help diagnoses, more.
The WHO and FIND are supporting NGS-based testing in low-resource settings, while a resistance testing program at New York State's Wadsworth Center has matured.